BioCentury
ARTICLE | Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

CEO Kerr sees ‘encouraging’ progress in area where biotechs have struggled to raise money

August 12, 2020 2:41 AM UTC
Updated on Aug 14, 2020 at 11:03 PM UTC

Bayer’s $425 million takeout of menopause play KaNDy sends a signal to investors that women’s health can deliver a return.

Private companies working in the space have long struggled to raise venture money...

BCIQ Company Profiles

Bayer AG

KaNDy Therapeutics Ltd.